CureVac BV (CVAC) Stock: What Does the Chart Say Wednesday?

Overall market sentiment has been high on CureVac BV (CVAC) stock lately. CVAC receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

CureVac BV has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CVAC!

See Full CVAC Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CVAC Stock Today?

CureVac BV (CVAC) stock is trading at $5.51 as of 1:22 PM on Wednesday, Nov 29, a rise of $0.01, or 0.18% from the previous closing price of $5.50. Volume today is 362,129 compared to average volume of 385,645. The stock has traded between $5.38 and $5.58 so far today. To screen for more stocks like CureVac BV click here.

More About CureVac BV

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases. Click Here to get the full Stock Report for CureVac BV stock.